Menu
Search
Home > Courses > R4P 2021: Updates on the HIV Pre-Exposure Prophylaxis Pipeline

R4P 2021: Updates on the HIV Pre-Exposure Prophylaxis Pipeline

R4P 2021: Updates on the HIV Pre-Exposure Prophylaxis Pipeline
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 4/14/2021
Termination Date: 04/13/2024
Review Date: 6/18/2021
Presenter
  • Craig W. Hendrix, MD
    Wellcome Professor and Director, Division of Clinical Pharmacology Departments of Medicine and Pharmacology
    Johns Hopkins University School of Medicine, Baltimore, MD
Presenter Bio
Craig Hendrix, MD

Craig W. Hendrix, MD is the Wellcome Professor and Director, Division of Clinical Pharmacology, at Johns Hopkins University School of Medicine. He trained in infectious diseases and clinical pharmacology at Hopkins before 10 years as an Air Force physician and 23 years at Johns Hopkins. Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis. He’s served as Principal Investigator of over 75 phase I clinical studies, mostly involving pre-exposure prophylaxis at Hopkins. He’s also served as principal pharmacologist for over 50 clinical trials in the Microbicide Trials Network and HIV Prevention Trials Network. He has published over 250 original scientific papers.

He greatly enjoys teaching and mentoring trainees at all levels and co-directs the Johns Hopkins T32 Clinical Pharmacology Training Program. He has received awards for teaching and mentoring from Johns Hopkins. He has also served as member of a National Academy of Medicine Advisory Panel, the CDC Board of Scientific Counselors, the board of several pharmacology professional societies, current Chairman of the Board of the American Board of Clinical Pharmacology, and member of several FDA Advisory Committees. He has received awards for scientific achievement from the PhRMA Foundation, the American College of Clinical Pharmacology, the American Society of Clinical Pharmacology and Therapeutics, and the FDA.

Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit on April 14, 2021 and will terminate April 13, 2023.

The target audience is all Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.


This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.


The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) has no relevant financial relationships to disclose.
  • Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose
  • Dr. Craig W. Hendrix (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research Funding: Gates, ViiV/GSK, Merck, Gilead managed by Johns Hopkins University; Advisory Boards: Population Council, RTI, PREVENT Program, Gilead, Merck, ViiV/GSK, Orion Biopharma; Founder/Officer of Prionde Biopharma. Dr. Hendrix will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details: 

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules